LLY
Eli Lilly's first quarter 2026 revenue surged 56% on GLP-1 drug sales, leading to a raised full-year outlook.
Eli Lilly reported first-quarter revenue of $19.8 billion, a 56% increase year-over-year, with non-GAAP EPS growing 156% to $8.55. These results were driven by...
